FDA Rejects Summit Therapeutics' Lung Cancer Drug Ivonescimab, Co-Developed With China's Akeso
The FDA issued a complete response letter declining to approve ivonescimab, a lung cancer treatment from Nasdaq-listed Summit Therapeutics and China's Akeso, because the drug did not show a statistically significant survival benefit. The decision is a setback for Summit, whose stock (SMMT) is the main US-listed exposure, and it tests whether data from Chinese trials can support US approval.
The US Food and Drug Administration has declined to approve ivonescimab, an experimental lung cancer treatment, Summit Therapeutics said in a statement on Sunday, November 15. The company, based in Miami and listed on the Nasdaq as SMMT, said it had received a complete response letter for its Biologics License Application covering the drug combined with platinum-based chemotherapy.
What the regulator objected to
The application covers patients with locally advanced or metastatic non-small cell lung cancer whose disease progressed after prior treatment with an EGFR tyrosine kinase inhibitor. According to Summit, the FDA concluded that the evidence of effectiveness was not established without a statistically significant improvement in overall survival.
Summit said the agency considered the benefit on progression-free survival, meaning how long the disease stays controlled, insufficient on its own to support approval. In the company's primary overall survival analysis, the combination showed a positive trend that did not reach statistical significance. Summit also cited a post-hoc analysis of longer follow-up in Western patients, which it said showed a consistent survival benefit across regions, but that analysis was not the basis the FDA used.
The company said the FDA's letter concluded that the application cannot be approved in its current form. Summit's release also reported that treatment-related discontinuations were 7.3% in the ivonescimab arm versus 5.0% in the placebo arm, and said the regimen showed no new safety signals.
Why the decision matters for US investors
Summit is a US-listed developer whose share price depends heavily on ivonescimab. The company holds development and commercialization rights outside China, while Akeso retains rights in China and some other markets. A rejection in the US removes near-term US approval for this indication and pushes out the commercial timeline for the drug in the country.
Summit's chairman and co-chief executive, Robert Duggan, said the company was disappointed for patients awaiting options in this setting. He also said the company remained committed to advancing the drug, pointing to five positive Phase III studies across Summit and Akeso. Summit's release said it will continue its broader development program, which includes several other Phase III trials in lung cancer and other tumor types.
The decision also matters beyond Summit. Ivonescimab is a PD-1 and VEGF bispecific antibody, and the class has drawn interest from large drugmakers. Trade coverage has framed the outcome as a test of whether strong results from Chinese trials can carry over to US regulatory standards, a point that bears on other US-listed companies that license Chinese-developed assets.
What is not yet known
Summit did not say whether it plans to resubmit the application. The company also did not say what additional data or analyses the FDA would need to reconsider the request. The letter itself had not been publicly posted at the time of the company's announcement, so the agency's full reasoning is available only through Summit's summary.
Summit has said it expects further late-stage data from a separate study in a different type of lung cancer by year-end, and investors will be watching those results as the company decides its next regulatory steps.
Sources
Written with AI assistance on Nov 15, 4:02 PM ET from the reports listed under Sources, and reviewed by our editor after publication. Before it was published, every figure was checked against those reports, and passages with figures that could not be found there were left out. It can still contain mistakes: read the sources before acting on anything. How we review. Not investment advice.